| Literature DB >> 34295789 |
Ming-Zhu Gui1,2, Ming Ni2,3, Xue-Dong Yin2, Ting Zhang4, Zhi-Ling Li2.
Abstract
Stevens-Johnson syndrome (SJS) is a disorder that causes severe damage to the skin and mucous membranes with bullous and erosive properties. Drug-induced liver injury (DILI) is closely related to non-steroidal anti-inflammatory drugs (such as ibuprofen). Liver injury caused by ibuprofen is often related to overdose, and liver injury caused by normal dose is rare, and there are individual differences in different situations. In this case, a child developed SJS and acute liver injury after treatment with ibuprofen suspension. We described the characteristics of related adverse reactions induced by ibuprofen, and analyzed the relationship between SJS caused by the drug and related drug genes. Glucocorticoids and antihistamines were used to treat dermatitis, reduced glutathione (GSH) to protect the liver and plasma exchange detoxification. Finally, the patient's dermatitis healed and the liver injury was significantly improved. Many studies have suggested that DILI may be related to human leukocyte antigen (HLA) genotyping. The detection of drug-related genes revealed that the SJS and liver damage caused by ibuprofen might have been related to the positive HLA-B*5801. This article suggests that attention should be paid to checking liver function indicators after taking ibuprofen, and genetic screening can be used to reduce the risk of gene-related adverse reactions when necessary. 2021 Translational Pediatrics. All rights reserved.Entities:
Keywords: Case report; Stevens-Johnson syndrome (SJS); drug gene testing; liver damage
Year: 2021 PMID: 34295789 PMCID: PMC8261580 DOI: 10.21037/tp-21-8
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
Figure 1A small red rash appeared on the neck and then spread to the face and body. As shown by the white arrow, there is a large area of bullous erythema multiforme.
Changes of liver function
| Date | Direct bilirubin (ìmol/L) | Total bilirubin (ìmol/L) | ALT (U/L) | AST (U/L) | γ-glutamyltransferase (U/L) | Total bile acid (ìmol/L) |
|---|---|---|---|---|---|---|
| 7.6 | 43.1 | 68.4 | 1,412 | 934 | 669 | 345.1 |
| 7.9 | 35 | 43 | 633 | 224 | 642 | 298.5 |
| 7.11 | 117.53 | 133.91 | 605 | 318 | 410 | 209 |
| 7.12 | 101.2 | 151.37 | 222 | 122 | 402 | 185 |
| 7.13 | 169.69 | 187.07 | 283 | 159 | 437 | 262 |
| 7.14 | 144.54 | 160.16 | 273 | 121 | 491 | 212 |
| 7.15 | 95.57 | 100.6 | 177 | 108 | 343 | 209 |
| 7.16 | 77.46 | 82.29 | 167 | 101 | 272 | 107 |
| 7.17 | 60.26 | 62.12 | 202 | 129 | 242 | 83 |
| 7.18 | 50.94 | 54.53 | 148 | 105 | 198 | 96 |
| 7.21 | 43.1 | 45.4 | 117 | 135 | 150 | 96 |
| 7.25 | 23.1 | 49.6 | 146 | 81 | 169 | 81 |
| 7.31 | 20.07 | 51.9 | 141 | 65 | 177 | 76 |
| 8.3 | 13 | 39.5 | 159 | 56 | 143 | 63 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Detection of HLA genes related to adverse drug reactions
| Test gene | Results |
|---|---|
| HLA-B*5801 | Positive |
HLA, human leukocyte antigen.
Figure 2Medication for children in hospital.
Figure 3Progression of the case according to the time line.